Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$122.84 USD
-2.16 (-1.73%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $122.86 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$122.84 USD
-2.16 (-1.73%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $122.86 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
by Zacks Equity Research
Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
by Zacks Equity Research
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
by Zacks Equity Research
Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
by Zacks Equity Research
Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 50.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Best Momentum Stocks to Buy for January 3rd
by Zacks Equity Research
SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
New Strong Buy Stocks for January 3rd
by Zacks Equity Research
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
by Sundeep Ganoria
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 82.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
by Zacks Equity Research
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
by Zacks Equity Research
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.